Prinzide (Lisinopril and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2018 Category: Drugs & Pharmacology Source Type: news
Atacand to be divested to Cheplapharm in Europe
AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Cheplapharm Arzneimittel GmbH (Cheplapharm). Atacand is a prescription medicine for the treatment of heart failure and hypertension. (Source: World Pharma News)
Source: World Pharma News - July 24, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets
Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceutical. The impurity detected in the API is N- nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International ...
Source: Food and Drug Administration - July 17, 2018 Category: Food Science Source Type: news
3 Companies Recall Blood Pressure Medications Over Cancer Fears
Some drugs used to control high blood pressure and prevent heart failure were voluntarily recalled this past week due to an impurity that could possibly lead to cancer, the U.S. Food and Drug Administration said.
These products — with the active ingredient valsartan, a generic drug used to treat high blood pressure — may contain N-nitrosodimethylamine (NDMA), a possible human carcinogen. The FDA asked three companies, Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd., to recall their valsartan products. Solco and Teva were also asked to recall their drugs containing valsartan/hydr...
Source: TIME: Health - July 17, 2018 Category: Consumer Health News Authors: Jennifer Calfas Tags: Uncategorized medicine onetime Source Type: news
FDA Recalls Common Heart Drug For Potential Cancer Risk
(CNN) — The recall of a common drug used to control blood pressure and help prevent heart failure was announced by the US Food and Drug Administration on Friday, a week after 22 other countries recalled it because the drug contains a chemical that poses a potential cancer risk.
Valsartan is off patent and is used as a component of other generic medicines, but not all medicines containing the ingredient are involved, according to the FDA. The US recall includes the the versions of valsartan that are made by Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals Industries Ltd. as well as valsartan/hydrochlor...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 16, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Valsartan Source Type: news
Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products
Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product lots. This impurity has been classified as a probable human carcinogen as per International Agency for Research on Cance...
Source: Food and Drug Administration - July 13, 2018 Category: Food Science Source Type: news
Class 1 Medicines Recall: Action Now including out of hours Pharmacy Level Recall: Superseded drug alert - Valsartan/Hydrochlorothiazide 160/12.5mg Film-Coated Tablets
The Medicines& Healthcare products Regulatory Agency (MHRA) issued a Class 1 Medicines Recall (Drug Alert EL (18)A/11) on 5th July 2018. Pharmacies in the UK were asked to recall all batches of v (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - July 11, 2018 Category: Drugs & Pharmacology Source Type: news
Hydrochlorothiazide and Risk of Hearing Disorder Hydrochlorothiazide and Risk of Hearing Disorder
While ototoxicity is not a known adverse effect of hydrochlorothiazide, this case series suggest there might be a causal relationship between its use and hearing disorder.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2018 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
Olmesartan Medoxomil and Hydrochlorothiazide Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 21, 2018 Category: Drugs & Pharmacology Source Type: news
Possible Link Between Hydrochlorothiazide and Malignant Melanoma Possible Link Between Hydrochlorothiazide and Malignant Melanoma
Long-term hydrochlorothiazide use appears to be associated with an increased risk of malignant melanoma, researchers from Denmark report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Hydrochlorothiazide Tied to Increased Melanoma Risk
(MedPage Today) -- Possible link pronounced for lentigo and nodular subtypes (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 29, 2018 Category: Dermatology Source Type: news
Hydrochlorothiazide and Lisinopril Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 22, 2018 Category: Drugs & Pharmacology Source Type: news
